Kong Yaojie, Li Jingyao, Zhao Xueyao, Wu Yanwei, Chen Liang
School of Medicine, Shanghai University, Shanghai, China.
Front Immunol. 2025 Jan 9;15:1519671. doi: 10.3389/fimmu.2024.1519671. eCollection 2024.
Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging. This review summarized the development of CAR-T technologies, emphasized the challenges and solutions in CAR-T cell therapy for solid tumors. Also, key innovations were discussed including specialized CAR-T, combination therapies and the novel use of CAR-Treg, CAR-NK and CAR-M cells. Besides, CAR-based cell therapy have extended its reach beyond oncology to autoimmune disorders. We reviewed preclinical experiments and clinical trials involving CAR-T, Car-Treg and CAAR-T cell therapies in various autoimmune diseases. By highlighting these cutting-edge developments, this review underscores the transformative potential of CAR technologies in clinical practice.
嵌合抗原受体(CAR)-T细胞疗法已迅速成为癌症治疗中的一种开创性方法,尤其是在血液系统恶性肿瘤治疗方面。然而,CAR-T细胞疗法在实体瘤中的应用仍然具有挑战性。本综述总结了CAR-T技术的发展,强调了CAR-T细胞疗法在实体瘤治疗中的挑战及解决方案。此外,还讨论了关键创新,包括特殊的CAR-T、联合疗法以及CAR-Treg、CAR-NK和CAR-M细胞的新用途。此外,基于CAR的细胞疗法已将其应用范围从肿瘤学扩展到自身免疫性疾病。我们回顾了涉及CAR-T、Car-Treg和CAAR-T细胞疗法在各种自身免疫性疾病中的临床前实验和临床试验。通过突出这些前沿进展,本综述强调了CAR技术在临床实践中的变革潜力。